PAI Pharma, a leading US developer of oral liquid medicines, has acquired Nivagen Pharmaceuticals, a California-based pharma company with a robust pipeline of ready-to-use (RTU) sterile injectables, to boost injectable drug production.
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing, strengthen supply-chain resilience, and accelerate growth in hospital-focused therapies—areas that continue to face persistent drug shortages across the US healthcare system.
Nivagen operates a state-of-the-art aseptic manufacturing facility in Sacramento, California, producing IV bags, vials, prefilled syringes, and cartridges. Its pipeline of over 20 RTU injectable products complements PAI’s existing sterile portfolio, which includes four marketed products and roughly 10 in development.
Together, the companies aim to better serve hospitals and health systems with high-quality, domestically manufactured sterile therapies.
“PAI is a market leader in RTU oral liquid medicines, and that same focus on quality, reliability, and patient-centric design carries naturally into RTU injectables,” said Kurt Orlofski, CEO of PAI Pharma.
“Olympus is proud to continue supporting PAI as it expands into sterile injectables,” said Griffin Barstis, Partner at Olympus Partners. “We believe the combination of PAI’s leadership in RTU oral liquids and Nivagen’s injectable platform creates a unique business that is well-positioned to serve hospitals and healthcare providers with critical, high-quality medicines.”
The deal aligns with national priorities to reshore pharmaceutical production, reduce reliance on foreign supply chains, and ensure consistent access to essential medicines. RTU injectables remain among the most shortage-prone therapies in the U.S., highlighting the urgent need for expanded domestic capacity.
“This acquisition represents a meaningful investment in American pharmaceutical manufacturing at a time when domestic capacity, reliability, and readiness matter more than ever,” said Jay Shukla, President of Nivagen Pharmaceuticals.
“This investment underscores the growing role Natomas and the Sacramento region are playing in strengthening America’s pharmaceutical manufacturing capacity,” said Congressman Ami Bera.
“This state-of-the-art facility is helping expand access to ready-to-use sterile injectable medicines, support hospital systems, and improve patient care. I appreciate PAI’s investment and look forward to working with them to position the Sacramento region for further growth.”
